Research location
Tachikawa
Japan
Advertisement
Research activity in Tachikawa
JapanCureCurrent currently publishes aggregate city-level research activity for this location: 8 trials and 10 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Tachikawa
8 linked trials · page 1 of 1A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)NCT07589595 · 2026-05-20 · 1 site observation
RECRUITING
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)NCT06653153 · 2024-10-24 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung CancerNCT06348199 · 2024-03-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's DiseaseNCT02906488 · 2016-09-12 · 1 site observation
COMPLETED
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart FailureNCT01877915 · 2013-09-10 · 1 site observation
COMPLETED
Safety and Efficacy of Daily Use of Micamlo® Combination Tablets AP in Patients With HypertensionNCT01353274 · 2011-05-01 · 3 site observations
COMPLETED
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)NCT01202188 · 2010-09-01 · 1 site observation
COMPLETED
Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term UseNCT01050062 · 2010-01-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.